Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2023-11-10 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim report' for the period January 1 to September 30, 2023, for Infant Bacterial Therapeutics AB. It contains comprehensive financial data, including income statements, balance sheets, cash flow, and earnings per share, as well as detailed management commentary (CEO message) and operational updates. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial analysis and statements for a period shorter than a full fiscal year. 9M 2023
2023-11-10 English
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2024
Board/Management Information Classification · 99% confidence The document is a press release dated October 24, 2023, announcing the formation and composition of the Nomination Committee for the upcoming Annual General Meeting (AGM) in 2024. This relates directly to the governance and preparation for the AGM. While it is an announcement, the content is specifically about the committee responsible for nominating directors and setting up the AGM process, which falls under the scope of AGM-related materials. Since the document is an announcement about the AGM structure rather than the meeting materials themselves (AGM-R) or a proxy solicitation (DEF 14A/PSI), and it is a specific announcement regarding the AGM process, 'AGM-R' (AGM Information) is the most appropriate fit, as it covers materials shared *for* the AGM, even if this is a preparatory announcement. Given the specific focus on the Nomination Committee for the AGM, it is more specific than a general Regulatory Filing (RNS).
2023-10-24 English
Infant Bacterial Therapeutics AB (publ) meddelar att valberedningen inför årsstämman 2024 bildats
Board/Management Information Classification · 99% confidence The document is a press release dated October 24, 2023, announcing that the Nomination Committee (Valberedningen) for the upcoming 2024 Annual General Meeting (Årsstämman) has been formed. It details the composition of this committee based on shareholder structure as of June 30, 2023. This announcement concerns the preparatory steps for the AGM, specifically regarding the nomination of board members and committee members. This falls under the scope of governance and shareholder meeting preparation. While it relates to the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (PSI). It is a specific announcement about the composition of a preparatory body for the AGM, which is closely related to Board/Management Information (MANG) or Governance Information (CGR). However, given the specific focus on the 'Valberedning' (Nomination Committee) formation process leading up to the AGM, and the lack of a specific code for 'Nomination Committee Formation', it is best classified as Governance Information (CGR) as it details internal rules/structure related to board composition, or potentially a Regulatory Filing (RNS) if it's considered a standard corporate governance disclosure. Since the content is entirely about the structure and process for selecting future board members/committee members, CGR is the most appropriate fit among the specific options, as it relates to corporate governance practices.
2023-10-24 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport 1 januari – 30 juni 2023' (Interim Report January 1 – June 30, 2023) for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, including income statements, balance sheets, cash flow data, and detailed management commentary on business performance, clinical trial progress, and financial risks for the six-month period. It is not an announcement of a report, but the report itself, containing substantive financial data. H1 2023
2023-08-25 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim report' for the period January 1-June 30, 2023, for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, selected financial data, a message from the CEO, and detailed analysis of business operations and risks. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2023
2023-08-25 English
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding ('Major Shareholding Notification') by 'Keel Capital' concerning shares in 'Infant Bacterial Therapeutics AB'. It specifies the 'Reason for major shareholding notification' as 'Sell', the date of the transaction (16/08/2023), and the resulting number of shares (642,191) and percentage (4.7671%). This content directly matches the definition of a Major Shareholding Notification, which corresponds to the code MRQ.
2023-08-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.